Jose Luis
Alonso Romero
Asociado Ciencias de la Salud
Pfizer (United States)
Nueva York, Estados UnidosPfizer (United States)-ko ikertzaileekin lankidetzan egindako argitalpenak (2)
2022
-
Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)
Lung Cancer, Vol. 173, pp. 83-93
-
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
European Journal of Cancer, Vol. 168, pp. 12-24